Skip to main content
Premium Trial:

Request an Annual Quote

Opko Completes $1.47B Buy of Bio-Reference

NEW YORK (GenomeWeb) – Opko today announced it has completed its $1.47 billion acquisition of Bio-Reference Laboratories.

Under the terms of the deal, which was announced in June, Bio-Reference's shareholders will receive 2.75 shares of Opko for each share of BRL's common stock that they own.

Based in Elmwood Park, New Jersey, Bio-Reference is the third-largest clinical laboratory in the US. Through its GeneDx genetic sequencing laboratory and its GenPath Diagnostics oncology and women's health business unit, Bio-Reference has accumulated a significant amount of genetic and genomic data that Opko will make available to industry and academic researchers to accelerate drug discovery and clinical trial programs. 

Opko is a biopharmaceutical and diagnostics firm headquartered in Miami. Its diagnostic services will be merged with Bio-References's operations, the firms said in June.

The Scan

Renewed Gain-of-Function Worries

The New York Times writes that the pandemic is renewing concerns about gain-of-function research.

Who's Getting the Patents?

A trio of researchers has analyzed gender trends in biomedical patents issued between 1976 and 2010 in the US, New Scientist reports.

Other Uses

CBS Sunday Morning looks at how mRNA vaccine technology could be applied beyond SARS-CoV-2.

PLOS Papers Present Analysis of Cervicovaginal Microbiome, Glycosylation in Model Archaea, More

In PLOS this week: functional potential of the cervicovaginal microbiome, glycosylation patterns in model archaea, and more.